Eintrag weiter verarbeiten
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Journal of Clinical Oncology, 29, 2011, 27_suppl, S. 134-134 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Arce Salinas, H. C. Ramirez-Morales, R. Aguila, C. Alvarado Miranda, A. Santamaria-Galicia, J. Cantu, D. Arce Salinas, H. C. Ramirez-Morales, R. Aguila, C. Alvarado Miranda, A. Santamaria-Galicia, J. Cantu, D. |
|---|---|
| author |
Arce Salinas, H. C. Ramirez-Morales, R. Aguila, C. Alvarado Miranda, A. Santamaria-Galicia, J. Cantu, D. |
| spellingShingle |
Arce Salinas, H. C. Ramirez-Morales, R. Aguila, C. Alvarado Miranda, A. Santamaria-Galicia, J. Cantu, D. Journal of Clinical Oncology Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. Cancer Research Oncology |
| author_sort |
arce salinas, h. c. |
| spelling |
Arce Salinas, H. C. Ramirez-Morales, R. Aguila, C. Alvarado Miranda, A. Santamaria-Galicia, J. Cantu, D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2011.29.27_suppl.134 <jats:p> 134 </jats:p><jats:p> Background: Breast cancer in older women has a tendency to increase its incidence; the prevalence and their clinical course are not reported. This group of patients is usually considered to be fragile; they receive dose levels of chemotherapy below standards. Objective: To compare the association of dose intensity with complete pathological response (cPR) in older women. </jats:p><jats:p> Methods: This is a retrospective analysis of patients treated with neoadjuvant anthracyclines, taxanes, or combination regimen from 2005 to 2008. Pathologic response was evaluated in the surgical specimen. </jats:p><jats:p> Results: We analyzed 801 cases, 694 (86.6%) patients were younger than 65 years-old and 107 (13.3%) were older than 65 years-old. Clinical stage, histological type and HER2 status were similar in both groups. High-grade lesions were more common in the younger group (61% vs. 41% p>0.05). ER+/PR+ were more frequent for the group >65 years-old (57.5/47% vs. 79.5/50%) p=NS. Triple-negative were 154 cases (22%) for younger patients and 14 cases (13%) for elderly women (p=0.02). Optimal dose intensity was above 80% of planned dose. For anthracycline-based regimen, older patients had more dose reduction (27.8%) in comparison to the younger group 2.1% (p= 0.00001), for the taxane regimen dose intensity was less than the standard in 8.8% of young population vs. 17.6% for older women (p = 0.03). The rate of cPR in younger patients was 20.3% vs. 11.1% in the older group (p<0.001). Toxicity profile was statistically similar in both groups. </jats:p><jats:p> Conclusions: Breast cancer has the same presentation in younger and in older patients. Older patients receive less dose intense chemotherapy. This is associated with a lesser rate of cPR. Therefore, older patient should be treated with full doses taking into account the toxicity profile of the chemotherapeutic regimens as well as the physical and medical conditions of the patient. </jats:p> Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2011.29.27_suppl.134 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS4yOS4yN19zdXBwbC4xMzQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS4yOS4yN19zdXBwbC4xMzQ |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2011 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
arcesalinas2011impactofdoseintensitychemotherapyingeriatricpopulationwithlocallyadvancedbreastcancertreatedinneoadjuvantsettingatthenationalcancerinstitutemexicocity |
| publishDateSort |
2011 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_unstemmed |
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_full |
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_fullStr |
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_full_unstemmed |
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_short |
Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_sort |
impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the national cancer institute, mexico city. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2011.29.27_suppl.134 |
| publishDate |
2011 |
| physical |
134-134 |
| description |
<jats:p> 134 </jats:p><jats:p> Background: Breast cancer in older women has a tendency to increase its incidence; the prevalence and their clinical course are not reported. This group of patients is usually considered to be fragile; they receive dose levels of chemotherapy below standards. Objective: To compare the association of dose intensity with complete pathological response (cPR) in older women. </jats:p><jats:p> Methods: This is a retrospective analysis of patients treated with neoadjuvant anthracyclines, taxanes, or combination regimen from 2005 to 2008. Pathologic response was evaluated in the surgical specimen. </jats:p><jats:p> Results: We analyzed 801 cases, 694 (86.6%) patients were younger than 65 years-old and 107 (13.3%) were older than 65 years-old. Clinical stage, histological type and HER2 status were similar in both groups. High-grade lesions were more common in the younger group (61% vs. 41% p>0.05). ER+/PR+ were more frequent for the group >65 years-old (57.5/47% vs. 79.5/50%) p=NS. Triple-negative were 154 cases (22%) for younger patients and 14 cases (13%) for elderly women (p=0.02). Optimal dose intensity was above 80% of planned dose. For anthracycline-based regimen, older patients had more dose reduction (27.8%) in comparison to the younger group 2.1% (p= 0.00001), for the taxane regimen dose intensity was less than the standard in 8.8% of young population vs. 17.6% for older women (p = 0.03). The rate of cPR in younger patients was 20.3% vs. 11.1% in the older group (p<0.001). Toxicity profile was statistically similar in both groups. </jats:p><jats:p> Conclusions: Breast cancer has the same presentation in younger and in older patients. Older patients receive less dose intense chemotherapy. This is associated with a lesser rate of cPR. Therefore, older patient should be treated with full doses taking into account the toxicity profile of the chemotherapeutic regimens as well as the physical and medical conditions of the patient. </jats:p> |
| container_issue |
27_suppl |
| container_start_page |
134 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
29 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792327951831793675 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:45:21.09Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Impact+of+dose+intensity+chemotherapy%2C+in+geriatric+population+with+locally+advanced+breast+cancer+treated+in+neoadjuvant+setting+at+the+National+Cancer+Institute%2C+Mexico+City.&rft.date=2011-09-20&genre=article&issn=1527-7755&volume=29&issue=27_suppl&spage=134&epage=134&pages=134-134&jtitle=Journal+of+Clinical+Oncology&atitle=Impact+of+dose+intensity+chemotherapy%2C+in+geriatric+population+with+locally+advanced+breast+cancer+treated+in+neoadjuvant+setting+at+the+National+Cancer+Institute%2C+Mexico+City.&aulast=Cantu&aufirst=D.&rft_id=info%3Adoi%2F10.1200%2Fjco.2011.29.27_suppl.134&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792327951831793675 |
| author | Arce Salinas, H. C., Ramirez-Morales, R., Aguila, C., Alvarado Miranda, A., Santamaria-Galicia, J., Cantu, D. |
| author_facet | Arce Salinas, H. C., Ramirez-Morales, R., Aguila, C., Alvarado Miranda, A., Santamaria-Galicia, J., Cantu, D., Arce Salinas, H. C., Ramirez-Morales, R., Aguila, C., Alvarado Miranda, A., Santamaria-Galicia, J., Cantu, D. |
| author_sort | arce salinas, h. c. |
| container_issue | 27_suppl |
| container_start_page | 134 |
| container_title | Journal of Clinical Oncology |
| container_volume | 29 |
| description | <jats:p> 134 </jats:p><jats:p> Background: Breast cancer in older women has a tendency to increase its incidence; the prevalence and their clinical course are not reported. This group of patients is usually considered to be fragile; they receive dose levels of chemotherapy below standards. Objective: To compare the association of dose intensity with complete pathological response (cPR) in older women. </jats:p><jats:p> Methods: This is a retrospective analysis of patients treated with neoadjuvant anthracyclines, taxanes, or combination regimen from 2005 to 2008. Pathologic response was evaluated in the surgical specimen. </jats:p><jats:p> Results: We analyzed 801 cases, 694 (86.6%) patients were younger than 65 years-old and 107 (13.3%) were older than 65 years-old. Clinical stage, histological type and HER2 status were similar in both groups. High-grade lesions were more common in the younger group (61% vs. 41% p>0.05). ER+/PR+ were more frequent for the group >65 years-old (57.5/47% vs. 79.5/50%) p=NS. Triple-negative were 154 cases (22%) for younger patients and 14 cases (13%) for elderly women (p=0.02). Optimal dose intensity was above 80% of planned dose. For anthracycline-based regimen, older patients had more dose reduction (27.8%) in comparison to the younger group 2.1% (p= 0.00001), for the taxane regimen dose intensity was less than the standard in 8.8% of young population vs. 17.6% for older women (p = 0.03). The rate of cPR in younger patients was 20.3% vs. 11.1% in the older group (p<0.001). Toxicity profile was statistically similar in both groups. </jats:p><jats:p> Conclusions: Breast cancer has the same presentation in younger and in older patients. Older patients receive less dose intense chemotherapy. This is associated with a lesser rate of cPR. Therefore, older patient should be treated with full doses taking into account the toxicity profile of the chemotherapeutic regimens as well as the physical and medical conditions of the patient. </jats:p> |
| doi_str_mv | 10.1200/jco.2011.29.27_suppl.134 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS4yOS4yN19zdXBwbC4xMzQ |
| imprint | American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2011 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:45:21.09Z |
| match_str | arcesalinas2011impactofdoseintensitychemotherapyingeriatricpopulationwithlocallyadvancedbreastcancertreatedinneoadjuvantsettingatthenationalcancerinstitutemexicocity |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 134-134 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Arce Salinas, H. C. Ramirez-Morales, R. Aguila, C. Alvarado Miranda, A. Santamaria-Galicia, J. Cantu, D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2011.29.27_suppl.134 <jats:p> 134 </jats:p><jats:p> Background: Breast cancer in older women has a tendency to increase its incidence; the prevalence and their clinical course are not reported. This group of patients is usually considered to be fragile; they receive dose levels of chemotherapy below standards. Objective: To compare the association of dose intensity with complete pathological response (cPR) in older women. </jats:p><jats:p> Methods: This is a retrospective analysis of patients treated with neoadjuvant anthracyclines, taxanes, or combination regimen from 2005 to 2008. Pathologic response was evaluated in the surgical specimen. </jats:p><jats:p> Results: We analyzed 801 cases, 694 (86.6%) patients were younger than 65 years-old and 107 (13.3%) were older than 65 years-old. Clinical stage, histological type and HER2 status were similar in both groups. High-grade lesions were more common in the younger group (61% vs. 41% p>0.05). ER+/PR+ were more frequent for the group >65 years-old (57.5/47% vs. 79.5/50%) p=NS. Triple-negative were 154 cases (22%) for younger patients and 14 cases (13%) for elderly women (p=0.02). Optimal dose intensity was above 80% of planned dose. For anthracycline-based regimen, older patients had more dose reduction (27.8%) in comparison to the younger group 2.1% (p= 0.00001), for the taxane regimen dose intensity was less than the standard in 8.8% of young population vs. 17.6% for older women (p = 0.03). The rate of cPR in younger patients was 20.3% vs. 11.1% in the older group (p<0.001). Toxicity profile was statistically similar in both groups. </jats:p><jats:p> Conclusions: Breast cancer has the same presentation in younger and in older patients. Older patients receive less dose intense chemotherapy. This is associated with a lesser rate of cPR. Therefore, older patient should be treated with full doses taking into account the toxicity profile of the chemotherapeutic regimens as well as the physical and medical conditions of the patient. </jats:p> Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. Journal of Clinical Oncology |
| spellingShingle | Arce Salinas, H. C., Ramirez-Morales, R., Aguila, C., Alvarado Miranda, A., Santamaria-Galicia, J., Cantu, D., Journal of Clinical Oncology, Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City., Cancer Research, Oncology |
| title | Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_full | Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_fullStr | Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_full_unstemmed | Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_short | Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| title_sort | impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the national cancer institute, mexico city. |
| title_unstemmed | Impact of dose intensity chemotherapy, in geriatric population with locally advanced breast cancer treated in neoadjuvant setting at the National Cancer Institute, Mexico City. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2011.29.27_suppl.134 |